Shares of vaccine makers closed lower Thursday amid reports that President-elect Donald Trump was set to nominate vaccine ...

Shares of BioNTech (BNTX) and Novavax (NVAX) closed with losses of 7%, while Moderna's stock (MRNA) shed 6%. Vaxcyte (PCVX) dropped 4%, and Pfizer (PFE) pulled back 3%. The sizeable declines in these ...

Vaccine stocks slid late Thursday as reports stated noted anti-vaccine politician Robert Kennedy Jr. will serve as the next ...

Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on CureVac (CVAC – Research Report), retaining the price target of $16.00.

Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled. A ...

Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled.

The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

CureVac (CVAC) has released an update. CureVac has reported a transformative third quarter with a strengthened cash position of €551 million ...

Belgium has solidified its position as a European leader in pharmaceutical research and development with a daily investment ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from ...